MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

161.80B

Vuru Grade

55.06/100

Current Price

$57.27
-0.40 (-0.69%)

Growth Price

$34.60
Overvalued by 39.58%

Stability Price

$19.99
Overvalued by 65.10%

Company Metrics

  • 14.88 P/E
  • 3.94 P/S
  • 3.41 P/B
  • 3.85 EPS
  • 12.10% Cash ROIC
  • 0.84 Cash Ratio
  • 1.80 / 3.10 % Dividend
  • 10.59M Avg. Vol.
  • 2.83B Shares
  • 161.80B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Company Shares of Merck & Company, Inc. Drops by -1.4%
OTC Outlook - 8 hours ago
Merck & Company, Inc. (NYSE:MRK) has lost 1.4% during the past week and dropped 2.24% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 0.23%.
Large Outflow of Money Witnessed in Merck & Company, Inc.
Money Flow Index - 4 hours ago
Merck & Company, Inc. (NYSE:MRK) jumped 0.07 points or 0.12% on strong buying and was last priced at $57.67 per share. The shares saw huge fund flow intraday; a massive $65.66 million made their way in through the upticks but an even bigger $111.65 ...
Hot Alert: VIVUS Inc. (NASDAQ:VVUS), Pfizer Inc. (NYSE:PFE), Merck & Co. Inc ... - Stock Transcript
Latest Alerts: AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE ... - Property Mentor
Merck & Co., Inc. (MRK) Stock Has Substantial Upside: Barron's
Bidness ETC - Jun 22, 2015
Merck & Co., Inc. (NYSE:MRK), the second-biggest US drug-maker by sales, currently boasts one of the industry's most promising new drug pipelines, according to Barron's.
Large Inflow of Money Witnessed in Merck & Company, Inc. - Insider Trading Report
Momentum Stock Watch: Merck & Company, Inc. (NYSE:MRK) - Enterprise Leader
Merck & Co., Inc. Betting High On Immunotherapy and HCV Drugs Market for ...
Bidness ETC - Jun 12, 2015
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug-maker by revenues, is working to reverse declining earnings caused by the patent expiry of several of its major blockbuster drugs.
Gilead Sciences, Inc. (GILD) Says Merck & Co., Inc. Won't Have Same Impact As ...
Bidness ETC - Jun 11, 2015
The next battle in the HCV landscape would be over a pan-genotypic 3-drug combo treatment instead of the drug with the cheaper price tag, said Gilead Sciences, Inc. (NASDAQ:GILD) president and chief operating officer John Milligan. The company said ...
Merck and Co. Inc.'s (NYSE:MRK) entry in the HCV market will not be the same ... - WallStreet.org
Hot News: Gilead Sciences Inc. (NASDAQ:GILD St. Jude Medical Inc. (NYSE ... - Stock Transcript
Stock Report on Merck & Co Inc (NYSE:MRK)
Markets Wired - Jun 10, 2015
[Business Wire] Merck & Co Inc (NYSE:MRK)(TREND ANALYSIS) known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled ...
TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint ... - Benzinga
Company Update (NYSE:MRK): TECOS, Merck's Cardiovascular Safety Trial of ... - Jutia Group
Merck & Co., GlaxoSmithKline plc, & Others Expected To Be Neck-And-Neck In ...
Bidness ETC - Jun 19, 2015
According to EvaluatePharma's (EP) World Preview 2015 report, the top four pharmaceutical companies in the vaccines market, Merck & Co., Inc. (NYSE:MRK), GlaxoSmithKline plc. (ADR) (NYSE:GSK), Sanofi SA(ADR) (NYSE:SNY), and Pfizer Inc.
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
Bidness ETC - Jun 25, 2015
Pfizer Inc. (NYSE:PFE), with global diabetes sales of $7.3 billion, and Eli Lilly, with $4.5 billion in sales, snagged the fourth and fifth spots on the list, respectively.
Shares of Merck & Company, Inc. (NYSE:MRK) Sees Large Inflow of Net Money ...
Insider Trading Report - Jul 1, 2015
Shares of Merck & Company, Inc. (NYSE:MRK) saw an erosion of -0.36 points in recent session. During the trading, the value of each share was $56.93, dropping -0.63%.
Pay Attention to These Stocks: Merck & Co. Inc. (NYSE:MRK), SunEdison Inc ... - Citizen Dispatch
Merck & Co. Raised to "Strong-Buy" at Vetr Inc. (MRK) - Dakota Financial News
Merck & Co. Inc (NYSE:MRK) Receives New Coverage at Piper Jaffray with ...
OctaFinance.com - Jun 18, 2015
In a research report shared with investors and clients on Wednesday morning, research analysts at Piper Jaffray has begun coverage on shares of Merck & Co. Inc (NYSE:MRK). The company issued “Neutral” rating on MRK stock. The initiation is well ...
Analyst Rating Update on Merck & Company, Inc. - News Watch International
Merck & Company, Inc. (NYSE:MRK) Price Target Update - OTC Outlook